Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539329 | 0.91 | PPARD (0.41) | PPARDTAAR1PIK3CARCE1MMP14 | |
| SCHEMBL6538962 | 0.88 | PPARD (0.39) | PPARDMEN1KMT2ATP53POLB | |
| SCHEMBL6539490 | 0.85 | PPARD (0.38) | PPARDTAAR1RCE1TP53POLB | |
| SCHEMBL6258240 | 0.85 | PPARD (0.40) | PPARDTAAR1PIK3CARCE1 | |
| SCHEMBL6539086 | 0.84 | MEN1 (0.45) | PPARDGRM5MEN1KMT2APOLB | |
| SCHEMBL6540113 | 0.84 | TP53 (0.39) | PPARDTAAR1RCE1MEN1KMT2A | |
| SCHEMBL6538808 | 0.82 | HSD17B1 (0.40) | PPARDPIK3CARCE1MEN1KMT2A | |
| SCHEMBL6539113 | 0.81 | RAB9A (0.48) | KMT2AATMPOLB | |
| SCHEMBL6539388 | 0.81 | PPARD (0.38) | PPARDATRTAAR1PIK3CALOXL2 | |
| SCHEMBL6325951 | 0.81 | PPARD (0.38) | PPARDATRTAAR1PIK3CALOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | PPARD 1747/4885ATR 4740/4885TAAR1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.